Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
4.540
0.00 (0.00%)
Feb 5, 2025, 9:31 AM EST - Market open
Lipocine Employees
Lipocine had 17 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$466,054
Profits / Employee
-$238,593
Market Cap
24.28M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
LPCN News
- 7 weeks ago - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PRNewsWire
- 2 months ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire
- 3 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PRNewsWire
- 3 months ago - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - PRNewsWire
- 4 months ago - Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PRNewsWire
- 4 months ago - Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PRNewsWire
- 4 months ago - Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - PRNewsWire
- 4 months ago - Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - PRNewsWire